Blake-Cerda M, Lozano-Ruíz F, Maldonado-Magos F, et al. - Researchers undertook this prospective, single-arm phase 2 trial to assess stereotactic ablative radiotherapy (SABR) as a local consolidative therapy (LCT) in patients with oligometastatic non-small cell lung cancer (NSCLC) patients. Patients suffering from stage IV NSCLC with ≤ five lesions, including the primary tumor, were included and treated with initial systemic therapy as per international guidelines. Using an 18F-FDG-PET/CT, experts assessed cases without progression following front-line therapy (2 months of targeted therapy and ≥ four cycles of chemotherapy) in order to deliver consolidative SABR (45−60 Gy in 3–5 fractions) to the primary as well as all intrapulmonary metastatic sites. Findings revealed not only good tolerability with SABR as LCT in oligometastatic NSCLC patients but also its efficacy in affording favorable outcomes with respect to progression-free survival and overall survival relative to the historical data. Disease control rate and complete metabolic response to SABR were 93.6% and 70.2%. A significantly higher benefit was noted in patients who reached a complete metabolic response as evaluated by 18F-FDG-PET/CT. For the total cohort, median PFS was 34.3 months; a median PFS of 53.9 months was seen in patients with a CMR vs 31.9 months in those without CMR.